Monitoring vs chemoradiation for early rectal cancer
Part of Cancer, Digestive system clinical trials.
This study compares two approaches after early-stage rectal cancer is removed: either careful monitoring or a follow-up treatment with chemotherapy and radiation. The goal is to see which strategy works better to keep the cancer from returning.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have had a type of rectal cancer that was completely removed through a scope or a small surgery, but it had high-risk features like poor differentiation, blood or lymph invasion, or deep growth.
- The tumor was no larger than 30mm (about 1.2 inches) and there's no sign of spread to lymph nodes or distant organs on scans.
- You are generally healthy (able to care for yourself), with good blood counts, liver, kidney, and heart function.
- You have not had prior radiation to the pelvis, and you don't have a known genetic cancer syndrome or inflammatory bowel disease.
- You are willing to be randomly assigned to either careful observation or additional chemoradiation to prevent the cancer from coming back.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at whether giving radiation or chemoradiation after removing an early-stage rectal cancer can improve outcomes for patients who choose not to have standard surgery to remove the whole rectum. It aims to see how well this approach works in real-world practice.
This study compares two standard treatment approaches for early-stage rectal cancer that has not spread. One group gets chemo and radiation before surgery, while the other gets chemo, radiation, and more chemo before surgery. The goal is to see which plan is more effective and has fewer side effects.
This study compares two treatment approaches for patients with locally advanced rectal cancer. One group gets a short course of radiation followed by chemotherapy combined with an immunotherapy drug called a PD-1 inhibitor, while the other group gets radiation and chemotherapy alone. The trial aims to see if the PD-1 inhibitor improves outcomes and whether a natural substance in the blood called beta-hydroxybutyrate can predict response.
This trial tests whether people with early- to intermediate-stage low rectal cancer can avoid surgery if their tumor responds well to a full course of chemotherapy and radiation. It starts with brief chemotherapy, then adjusts treatment based on how much the tumor shrinks.
This trial studies people with early-to-mid stage distal rectal cancer who may get radiation and chemotherapy, with an option that may include an extra drug (oxaliplatin). It also tests whether some people can safely follow a “watch and wait” plan instead of immediate additional treatment, aiming to reduce overtreatment while keeping cancer control.
This trial compares two approaches for early-stage rectal cancer: chemotherapy plus local surgery versus standard chemoradiotherapy. It aims to see if less intensive treatment can work just as well, reducing side effects.
Hear when a new Rectal Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.